Search - tctmd.com

Displaying 1 - 4 of 4

Sort: Relevancy | Date

Prospective, Controlled, Clinical Randomized Trial Evaluating Novel, Microcrystalline and Biodegradable Polymer Paclitaxel Coated Balloon for the Treatment of Femoro-popliteal Disease (The BIOPAC trial) - One Year Outcome

Presentation TCT 2017

Prospective, Controlled, Clinical Randomized Trial Evaluating Novel, Microcrystalline and Biodegradable Polymer Paclitaxel Coated Balloon for the Treatment of Femoro-popliteal Disease (The BIOPAC trial) - One Year Outcome

Presenter: Mahmood K. Razavi, Krishna J. Rocha-Singh, Piotr P. Buszman

November 01, 2017

The PRELUDE Study: Prospective Study for the Treatment of Atherosclerotic Lesions in the Superficial Femoral and/or Popliteal Arteries Using the Serranator® Device

Presentation TCT 2017

The PRELUDE Study: Prospective Study for the Treatment of Atherosclerotic Lesions in the Superficial Femoral and/or Popliteal Arteries Using the Serranator® Device

Presenter: Tony Das, Thomas Zeller, William A. Gray

October 30, 2017

RESPECT: Final Long-term Outcomes From a Prospective, Randomized Trial of PFO Closure in Patients With Cryptogenic Stroke

Presentation TCT 2016

RESPECT: Final Long-term Outcomes From a Prospective, Randomized Trial of PFO Closure in Patients With Cryptogenic Stroke

Presenter: Howard C. Herrmann, Robert J. de Winter, David E. Thaler

November 01, 2016

Twelve-Month Safety and Efficacy of CGuard Micro-Net-Covered Embolic Prevention System: Routine Use to Perform Carotid Revascularization in Symptomatic and Increased Stroke Risk Asymptomatic Patients: The PARADIGM All-Comer Prospective Study

Presentation TCT 2016

Twelve-Month Safety and Efficacy of CGuard Micro-Net-Covered Embolic Prevention System: Routine Use to Perform Carotid Revascularization in Symptomatic and Increased Stroke Risk Asymptomatic Patients: The PARADIGM All-Comer Prospective Study

Presenter: Robert M. Bersin, John R. Laird Jr., Piotr Musialek

November 01, 2016

Country

First Name

Last Name

Email

Profession

Organization

Country

CAPTCHA

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.